Actively Recruiting
Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs)
Led by University of Pisa · Updated on 2026-04-09
100
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Direct oral anticoagulants (DOACs) are increasingly used, but evidence on bleeding risk during oral soft tissue biopsy is limited. This prospective case-control study compared intraoperative, perioperative, and postoperative bleeding in 50 patients on uninterrupted DOAC therapy versus 50 anticoagulant-naive controls undergoing standardized oral soft tissue biopsy with suturing. All bleeding events were managed with local haemostatic measures. The study aims to determine whether DOAC continuation is safe for this procedure.
CONDITIONS
Official Title
Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and sign informed consent
- Documented need for oral soft tissue biopsy
You will not qualify if you...
- Unable to provide informed consent
- Congenital or acquired bleeding disorders including haemophilia, von Willebrand disease, thrombocytopenia, or liver cirrhosis
- Current use of antiplatelet therapy other than low-dose aspirin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Pisa
Pisa, Pi, Italy, 56126
Actively Recruiting
Research Team
M
Marco Nisi, Prof.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here